

CIBINQO PRIOR APPROVAL REQUEST Send completed form to: Service Benefit Plan **Prior Approval** P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 **Attn. Clinical Services**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Fax: 1-877-378-4727

Patient Information (required)			Provider Information (required)			
Date:			Provider Name:			
Patient Name:			Specialty:	NPI:		
Date of Birth:	Sex: □Male □Female		Office Phone:	Office Fax	Office Fax:	
Street Address:			Office Street Address:			
City:	State:	Zip:	City:	State:	Zip:	
Patient ID:		1	Physician Signature:	I		
PHYSICIAN COMPLETES						
Cibinqo (abrocitinib)						
**Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit						
NOTE: Form must be completed in its entirety for processing						
Is this request for brand or generic? □Brand □Generic						
How many tablets will the patient need for a 90 day supply? tablet(s) per 90 days						
1. What is the patient's diagnosis?						
☐ Atopic dermatitis (eczema)						
☐ Other diagnosis (please specify):						
2. Has the prescriber considered the risks for malignancy and major adverse cardiovascular events (MACE) (such as advanced age, smoking history, cardiovascular risk factors etc.) and determined that Cibinqo therapy is appropriate? \[\textsim \text{No} \]						
3. Does the patient have any active bacterial, invasive fungal, viral, or other opportunistic infections present? □Yes □No						
4. Will the patient be given live vaccines while on Cibinqo? □Yes □No						
5. Will Cibinqo be used in combination with another *non-topical Prior Authorization (PA) medication for atopic dermatitis? \Box Yes* \Box No						
*If YES, please specify medication: *Non-Topical PA Medications: Adbry (tralokinumab-ldrm), Dupixent (dupilumab), Rinvoq (upadactinib)						
*Non-Topical PA Medications: Adbry (tralokinumab-ldrm), Dupixent (dupilumab), Rinvoq (upadactinib) 6. Has the patient been on Cibingo continuously for the last 3 months, excluding samples? Please select answer below:						
□ NO – this is INITIATION of therapy, please answer the following questions:						
a. Does the patient have moderate to severe atopic dermatitis (eczema)? \square Yes \square No						
b. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to at least TWO systemic atopic dermatitis medications, including biologics (e.g., oral corticosteroids, hydroxyzine, Adbry, Dupixent, Rinvoq, etc)? □Yes □No						
c. Has the patient been tested for latent tuberculosis (TB)? \(\sigma\)Yes* \(\sigma\)No						
If YES, was the result of the test positive or negative for TB infection? \(\simethat{D}\)Negative \(\simethat{D}\)Positive						
-	•		the patient currently receiving to $C_{\text{loss}}(C)$? $\Box V_{\text{os}} = \Box V_{\text{os}}$	reatment for lat	ent TB? □Yes □No	
d. Does the patient have severe hepatic impairment (Child-Pugh Class C)? ☐Yes ☐No e. Does the patient have a lymphocyte count less than 500 cells per cubic millimeter (cells/mm3)? ☐Yes ☐No						
f. Does the patient have an absolute neutrophil count (ANC) less than 1000 cells per cubic millimeter (cells/mm3)? \(\sigma\) Yes \(\sigma\)No						
g. Does the patient have a hemoglobin less than 8 grams per deciliter (g/dL)? \(\sigma\)Yes \(\sigma\)No						
h. Does the patient have a history of thrombotic events including deep vein thrombosis (DVT) or pulmonary embolism (PE)? □Yes □No						
i. Will Cibinqo be used in combination with antiplatelet therapy during the first three months of treatment (excluding low-dose aspirin less than or equal to 81 mg daily)? □Yes □No						
☐ YES – this is a PA renewal for	or CONTINUAT	ION of therapy	, please answer the following	questions:		
a. Has the patient's condition improved or stabilized with therapy? □Yes □No						
 b. Has the patient developed any thrombotic events, including deep vein thrombosis (DVT) or pulmonary embolism (PE)? □Yes □No 						



CIBINQO PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan **Prior Approval** P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 **Attn. Clinical Services** Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA.
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. Please only fax the completed form once as duplicate submissions may delay processing times.

faster... Introducing ePA! Online Prior Authorizations in minutes through Caremark.com/ePA. Sign up today!

CVS/caremark

